GlassScriptPhysician profile
Vanessa T Barrow
NPI 1356513626
$847.52
in general payments reported to CMS, 2019-2025
10 companies · $578 in 2025
The $578 reported for 2025 was more than what 75% of Foot Surgery providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.38 · 2021: $50.24 · 2023: $19.97 · 2024: $164 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569 · Travel and Lodging: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.25 |
| Travel and Lodging | $192.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $360.67 | 2024-2025 | |
| Revance Therapeutics, INC. | $111.14 | 2024 | Daxxify |
| Stryker Corporation | $107.60 | 2025 | N/A |
| Convatec INC. | $95.70 | 2024-2025 | |
| Crossroads Extremity Systems, LLC | $50.24 | 2021 | |
| Merck Sharp & Dohme LLC | $35.38 | 2019 | |
| Smith+Nephew, INC. | $27.35 | 2025 | Stravix Pl |
| Lilly USA, LLC | $21.29 | 2025 | Amyvid, Kisunla |
| Sk Life Science, INC. | $19.97 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.18 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Barrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.